Trial Profile
Multi-Centre, Prospective, Observational Study of Patient Reported Outcomes in Patients Diagnosed With Chronic Migraine and Treated With OnabotulinumtoxinA for Injection (BOTOX) (PREDICT)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Feb 2023
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Acronyms PREDICT
- Sponsors Allergan
- 10 Dec 2022 Results assessing the real-world effectiveness and safety of 155U, 156-195U and 195U onabotulinumtoxinA (onabotA) in patients with chronic migraine (CM) from the PREDICT study, presented at the 16th European headache federation Congress.
- 01 Jul 2022 Results assessing real-world, long-term health-related quality of life in adults with chronic migraine receiving onabotulinumtoxinA, published in the Canadian Journal of Neurological Sciences.
- 12 Jun 2022 Results (n=184) presented at the 64th Annual Scientific Meeting of the American Headache Society.